Cancer Treatment Centers of America | Strategic Alliance Partners

July 30, 2013

Patients diagnosed with cancer today are considered to be genuine partners in all major treatment decisions. Yet, how well do they understand the nature and goals of genetic testing that might be recommended as part of the management of their disease?

March 01, 2013

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

February 06, 2013

Maurie Markman, MD, asks who should decide whether it is ethically valid to consider off-label treatment in a patient with a very serious medical illness.

January 04, 2013

In the absence of a phase III randomized trial, what constitutes sufficient evidence to justify use of a treatment, particularly a nontraditional treatment or one that challenges common practice?